{
    "article_id": 1404,
    "public_id": "5fd3d156-2e47-4537-9e2b-0030750ce386",
    "internal_identifier": null,
    "source_identifier": "87:63",
    "status": "published",
    "type": "research_article",
    "title": "Pankreas kanserli hastalarda CA19-9’un prognostik değeri",
    "title_secondary": null,
    "abstract": "Farklı prognostik biomarkerların prediktif önemi çeşitli kanser tiplerinde çalışılmıştır. Çalışmamızın amacı metastatik pankreas kanserli hastalarda tedavi öncesi CA19-9 değerlerinin risk derecesini ve prognostik önemini belirleyerek sağkalım ile ilişkisini ortaya çıkarmaktır. Çalışmamızda 58 metastatik pankreas kanser hastasının tanı anındaki klinik ve laboratuvar verileri retrospektif olarak analiz edildi. Genel sağkalım süreleri Kaplan-Meier metodu ile hesaplandı. Pankreas kanserini etkileyen prognostik faktörleri belirlemek için Cox regresyon analizi yapıldı. Hastaların ortalama yaş 66 ± 3,25 idi.  Takip süresince analize alınan hastaların genel medyan  sağkalımı 13 ay  (%95 CI 9.73-15.26) olarak saptandı. ROC curve analizine göre  CA19-9 için cut-off değeri 437 ([AUC]:0.670,95%CI[0.57 to 0.75], p=0.002) olarak hesaplandı. Multivariate  Cox regresyon analizi sonucunda; CA19-9 (≥437 vs <437, HR=1.81, 95 % CI 1.08- 3.03 p=0.022), genel sağkalım (OS) analizinde önemli prognostik faktör olarak bulundu. Çalışmamızda metastatik PC’li hastalarda tedavi öncesi CA19-9 kötü prognoz için güvenilir prediktif markerlar olduğu belirlenmiştir. Çalışmamızın sonuçlarına göre CA19-9 Pankreas kanserli hastaların sağkalım tahmininde kullanılabilir. Elde ettiğimiz bulguların metastatik pankreas kanser tanılı hastaların tedavi protokollerinin yönetilmesinde kliniğe ışık tutacağı inancındayız. ",
    "language": "tr",
    "english_title": "Prognostic value of CA19-9 in patients with pancreatic cancer.",
    "english_abstract": "The purpose of this study was to examine the degree of risk and prognostic significance of pre-treatment carbohydrate antigen 19-9 levels in patients with metastatic pancreatic cancer and reveal its relevance with survival. Clinical and laboratory data of 58 patients with metastatic pancreatic cancer at the time of diagnosis were retrospectively analyzed. Overall survival (OS) was estimated according to Kaplan-Meier method. In order to determine the prognostic factors affecting pancreatic cancer the Cox regression analysis was performed. The average age of the patients was 66 ± 3.25 years. The patients were analyzed during the follow-up period, and their average OS was 13 months (95% CI 6.73–15.26). Pre-treatment CA19-9 levels were found to be reliable predictive markers for poor prognosis in patients with metastatic pancreatic cancer. Our findings revealed that CA19-9 levels can be used to estimate the survival of patients with pancreatic cancer. We believe that our findings will shed light on the management of treatment protocols for patients diagnosed with metastatic pancreatic cancer.",
    "doi": "10.36287/setsci.4.9.063",
    "doi_url": "https://doi.org/10.36287/setsci.4.9.063",
    "resource_url": "https://www.set-science.com/a/5fd3d156-2e47-4537-9e2b-0030750ce386",
    "pdf_url": "https://www.set-science.com/a/5fd3d156-2e47-4537-9e2b-0030750ce386/pdf",
    "og_image": "https://www.set-science.com/assets/img/og-card-v2.png",
    "authors": [
        {
            "public_id": "ddcce5e7-d5b5-43d6-a860-984c34089a1a",
            "given": "Şirin",
            "family": "Çetin",
            "full": "Şirin Çetin",
            "literal": null,
            "orcid": null,
            "orcid_url": null,
            "email": "cetinsirin55@gmail.com",
            "corresponding": true,
            "sequence": "first",
            "affiliations": [
                {
                    "name": "Tokat Gaziosmanpaşa University",
                    "department": null,
                    "country": null,
                    "country_code": null,
                    "ror": null,
                    "ror_url": null
                }
            ]
        },
        {
            "public_id": "7a56b5cb-457c-496d-92d2-0a1b0791ff93",
            "given": "İsa",
            "family": "Dede",
            "full": "İsa Dede",
            "literal": null,
            "orcid": null,
            "orcid_url": null,
            "email": "drdede@mynet.com",
            "corresponding": false,
            "sequence": "additional",
            "affiliations": [
                {
                    "name": "Mustafa Kemal University",
                    "department": null,
                    "country": null,
                    "country_code": null,
                    "ror": null,
                    "ror_url": null
                }
            ]
        },
        {
            "public_id": "56388759-43ff-4a4c-9bd0-a9886194bcf2",
            "given": "Meryem",
            "family": "Çetin",
            "full": "Meryem Çetin",
            "literal": null,
            "orcid": null,
            "orcid_url": null,
            "email": "meryemcetin55@yahoo.com",
            "corresponding": false,
            "sequence": "additional",
            "affiliations": [
                {
                    "name": "Tokat Gaziosmanpaşa University",
                    "department": null,
                    "country": null,
                    "country_code": null,
                    "ror": null,
                    "ror_url": null
                }
            ]
        }
    ],
    "keywords": [],
    "translations": [
        {
            "language": "en",
            "title": "Prognostic value of CA19-9 in patients with pancreatic cancer.",
            "abstract": "The purpose of this study was to examine the degree of risk and prognostic significance of pre-treatment carbohydrate antigen 19-9 levels in patients with metastatic pancreatic cancer and reveal its relevance with survival. Clinical and laboratory data of 58 patients with metastatic pancreatic cancer at the time of diagnosis were retrospectively analyzed. Overall survival (OS) was estimated according to Kaplan-Meier method. In order to determine the prognostic factors affecting pancreatic cancer the Cox regression analysis was performed. The average age of the patients was 66 ± 3.25 years. The patients were analyzed during the follow-up period, and their average OS was 13 months (95% CI 6.73–15.26). Pre-treatment CA19-9 levels were found to be reliable predictive markers for poor prognosis in patients with metastatic pancreatic cancer. Our findings revealed that CA19-9 levels can be used to estimate the survival of patients with pancreatic cancer. We believe that our findings will shed light on the management of treatment protocols for patients diagnosed with metastatic pancreatic cancer.",
            "keywords": [
                "Metastatik pankreas kanser, CA19-9, prognostik faktör"
            ]
        }
    ],
    "subjects": [],
    "subject_names": [],
    "published_date": "2019-12-23",
    "published_year": "2019",
    "received_date": null,
    "accepted_date": null,
    "volume": "12",
    "issue": null,
    "page_first": "96",
    "page_last": "98",
    "article_number": null,
    "conference": {
        "short_name": "ISAS WINTER-2019 (HSS)",
        "full_title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "name": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "acronym": "ISAS WINTER-2019 (HSS)",
        "location": "Samsun, Türkiye",
        "start_date": "2019-11-22",
        "end_date": null,
        "public_id": "76ee0eb0-7f71-420c-9d1c-2b81a3a76e96"
    },
    "proceedings": {
        "title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "series_title": "SETSCI Conference Proceedings",
        "publisher": "SET Technology",
        "isbn": "978-605-81988-9-0",
        "eisbn": null,
        "issn": null,
        "eissn": "2687-5527",
        "doi": null,
        "doi_prefix": "10.36287",
        "slug": "setsci-volume-12-2019-legacy-87",
        "public_id": "083b6600-6489-43ad-9a7d-d9fd7505e910",
        "url": "https://www.set-science.com/p/setsci-volume-12-2019-legacy-87"
    },
    "license": {
        "name": "CC BY 4.0",
        "url": "https://creativecommons.org/licenses/by/4.0/",
        "code": "CC-BY-4.0",
        "open_access": true
    },
    "copyright": {
        "holder": "SET Technology",
        "year": "2019"
    },
    "funding_statement": null,
    "funders": [],
    "references": [
        {
            "order": 1,
            "raw": "1.\tLiu Z, Luo G, Guo M, et al. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology. 2015;3:253–8. \r\n2.\tXu MD, Liu SL, Feng YZ, Liu Q, Shen M, Zhi Q, Liu Z, Gu DM, Yu J, Shou LM, Gong FR, Zhu Q, Duan W, et al. Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. Oncotarget. 2017; 8:14620-14635. https://doi.org/10.18632/ oncotarget.14678. \r\n3.\t Gong FR, Wu MY, Shen M, Zhi Q, Xu ZK, Wang R, Wang WJ, Zong Y, Li ZL, Wu Y, Zhou BP, Chen K, Tao M, Li W. PP2A inhibitors arrest G2/M transition through JNK/ Sp1- dependent down-regulation of CDK1 and autophagydependent up-regulation of p21. Oncotarget. 2015; 6:18469- 18483. https://doi.org/10.18632/oncotarget.4063. \r\n4.\tMichaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111. \r\n5.\tLuo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H, Zhang S, Long J, Xu J, Ni Q, Chen J, Yu X. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett. 2017 Dec;14(6):6795-6800. doi: 10.3892/ol.2017.7071. Epub 2017 Sep 26. \r\n6.\tCoussens LM, Werb Z. Inflammation and cancer. Nature. 2002;6917:860–7. \r\n7.\tGrivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140:883–899. \r\n8.\tMantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454:436–444. \r\n9.\tSchmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005;93(3):273e8.  \r\n10.\tScara S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol 2015;867:247–60. \r\n11.\tZhang DX, Dai YD, Yuan SX, Tao L. Exp Ther Med. 2012 Mar;3(3):423-432. Epub 2011 Dec 8. Prognostic factors in patients with pancreatic cancer. \r\n12.\tGao Y, Wang WJ, Zhi Q, Shen M, Jiang M, Bian X, Gong FR, Zhou C, Lian L, Wu MY, Feng J, Tao M, Li W. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017 Sep 27;8(51):88835-88844. \r\n13.\tPeixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015 Aug;4(8):1171-7. \r\n14.\tRosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002;16:37-52. \r\n15.\tLuo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, et al: Modified staging clas¬sification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol 35: 274 280, 2017.  \r\n16.\tHuang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol 2014;35:7459-65. ",
            "doi": null,
            "title": null,
            "authors": null,
            "source": null,
            "year": null,
            "volume": null,
            "pages": null
        }
    ],
    "statements": {
        "acknowledgements": null,
        "conflict_of_interest": null,
        "data_availability": null,
        "ai_disclosure": null
    },
    "credit": [],
    "history": {
        "published": "2019-12-23"
    }
}